These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 549256)

  • 1. Hemodynamic effects of intravenous and oral amrinone in patients with severe heart failure: relationship between intravenous and oral administration.
    LeJemtel TH; Keung EC; Schwartz WJ; Maskin CS; Greenberg MA; Davis RS; Forman R; Ribner HS; Sonnenblick EH
    Trans Assoc Am Physicians; 1979; 92():325-33. PubMed ID: 549256
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hemodynamic effects of various doses of a new inotropic: amrinoma].
    Cárdenas M; Vidaurri A
    Arch Inst Cardiol Mex; 1979; 49(5):961-8. PubMed ID: 122781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effects of intravenous amrinone in patients with congestive heart failure.
    Goldstein RA
    Circulation; 1986 Mar; 73(3 Pt 2):III191-5. PubMed ID: 3510775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous amrinone for congestive heart failure.
    Med Lett Drugs Ther; 1984 Nov; 26(675):104-5. PubMed ID: 6390109
    [No Abstract]   [Full Text] [Related]  

  • 5. Amrinone in severe congestive heart failure: another look at an intriguing new cardioactive drug.
    Hermiller JB; Leithe ME; Magorien RD; Unverferth DV; Leier CV
    J Pharmacol Exp Ther; 1984 Feb; 228(2):319-26. PubMed ID: 6694112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of amrinone administered orally and by injection in heart failure].
    Bounhoure JP; Massabuau P; Puel J; Miquel JP; Calazel J
    Ann Med Interne (Paris); 1985; 136(3):251-5. PubMed ID: 3896092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute haemodynamic effects of intravenous amrinone in chronic congestive heart failure.
    Bahl VK; Khalilullah M
    Indian Heart J; 1984; 36(6):369-74. PubMed ID: 6535755
    [No Abstract]   [Full Text] [Related]  

  • 8. [Amrinone in acute and long-term therapy].
    Klepzig M; Kleinhans E; Büll U; Strauer BE
    Z Kardiol; 1985 Feb; 74(2):85-90. PubMed ID: 3922139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amrinone: a promising new cardiotonic agent in the treatment of chronic cardiac failure.
    Likoff MJ; Weber KT; Andrews V; Janicki JS
    Herz; 1983 Aug; 8(4):199-205. PubMed ID: 6413341
    [No Abstract]   [Full Text] [Related]  

  • 10. Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure.
    Packer M; Medina N; Yushak M
    Am J Cardiol; 1984 Nov; 54(8):1025-9. PubMed ID: 6496324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-glycoside, non-catecholamine inotropic agents in the treatment of congestive heart failure.
    Tommaso CL
    Am J Med; 1986 Feb; 80(2B):36-9. PubMed ID: 3004210
    [No Abstract]   [Full Text] [Related]  

  • 12. Positive inotropic effect of 3, 4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-qu inolinone (OPC-8212) in the dog with experimentally-induced right-sided heart failure.
    Hashimoto K; Yabuuchi Y; Yamashita S; Mori T
    Arzneimittelforschung; 1984; 34(3A):390-3. PubMed ID: 6540094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amrinone--a new inotropic agent in chronic resistant congestive cardiac failure.
    Robinson PJ; Lvoff R; Chong B; Barrett PA
    Aust N Z J Med; 1981 Dec; 11(6):666-8. PubMed ID: 6949545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The hemodynamic profile of amrinone and enoximone in patients with severe heart failure].
    Saborowski F; Peters P; Schneider M
    Z Kardiol; 1991; 80 Suppl 4():63-7. PubMed ID: 1833900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hemodynamic and clinical effects and treatment tolerance with low-dose iv amrinone in patients with refractory heart failure: a multicenter study. The Group for Research on Amrinone in the Treatment of Refractory Heart Failure].
    Dei Cas L; Metra M; Nodari S; Raddino R; Visioli O
    Cardiologia; 1991 May; 36(5):363-71. PubMed ID: 1756541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oral and injectable amrinone in cardiac insufficiency].
    Massabuau P; Puel J; Miquel JP; Bounhoure JP
    Ann Cardiol Angeiol (Paris); 1984; 33(4):223-6. PubMed ID: 6465816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haemodynamic effects of amrinone infusion in patients with chronic heart failure.
    Manoharan S; Yadav BS; Tyagi S; Rao DK; Puri YK; Singh PP; Lochan R; Khalilullah M
    Indian Heart J; 1986; 38(5):362-6. PubMed ID: 3570319
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics of the bipyridines amrinone and milrinone.
    Edelson J; Stroshane R; Benziger DP; Cody R; Benotti J; Hood WB; Chatterjee K; Luczkowec C; Krebs C; Schwartz R
    Circulation; 1986 Mar; 73(3 Pt 2):III145-52. PubMed ID: 3510771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amrinone and exercise performance in patients with chronic heart failure.
    Weber KT; Andrews V; Janicki JS; Wilson JR; Fishman AP
    Am J Cardiol; 1981 Jul; 48(1):164-9. PubMed ID: 7246438
    [No Abstract]   [Full Text] [Related]  

  • 20. Chronic oral amrinone therapy in congestive heart failure: a double-blind placebo-controlled withdrawal study.
    Evans JR; Pacht K; Huss P; Unverferth DV; Bashore TM; Leier CV
    Int J Clin Pharmacol Res; 1984; 4(1):9-18. PubMed ID: 6381344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.